Advertisement

Tumor Biology

, Volume 36, Issue 5, pp 3195–3196 | Cite as

Letter regarding Li JS et al. entitled “ERCC polymorphisms and prognosis of patients with osteosarcoma”

  • Yuekui Jian
  • Xiaobin Tian
  • Bo Li
  • Zhuojia Zhou
  • Xinglin Wu
Research Commentary

Abstract

With great interest, we read the article “ERCC polymorphisms and prognosis of patients with osteosarcoma” (by Li JS et al.), which has reached important conclusions about the relationship between ERCC polymorphisms and osteosarcoma prognosis. Through quantitative analysis, the meta-analysis showed that ERCC2 Lys751Gln (ORGG vs. AA = 0.40 (95%CI = 0.1–0.86), P heterogeneity = 0.502; I 2 = 0 %) and ERCC5 His46His (ORCC vs. TT = 0.37 (95%CI = 0.15–0.93), P heterogeneity = 0.569; I 2 = 0 %) polymorphisms might influence the prognosis of patients with osteosarcoma [1]. The meta-analysis results are encouraging. Nevertheless, some deficiencies still existed that we would like to raise.

Keywords

ERCC Osteosarcoma Polymorphisms Prognosis Meta-analysis 

Notes

Acknowledgements

This work was support by Innovative talents team project Guizhou, China (Guizhou Science Cooperation(No.20114102).

Conflicts of interest

None

Reference

  1. 1.
    Li JS, Liu SH, Wang WG, et al. ERCC polymorphisms and prognosisof patients with osteosarcoma. Tumor Biol. 2014;35:10129–36.CrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Yuekui Jian
    • 1
  • Xiaobin Tian
    • 1
  • Bo Li
    • 1
  • Zhuojia Zhou
    • 1
  • Xinglin Wu
    • 1
  1. 1.Department of OrthopaedicsThe Affiliated People’s Hospital Guiyang Medical CollegeGuiyangChina

Personalised recommendations